Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Biotechnology

Healthcare
$29.68 +1.50%

+$0.50 today

Market cap
$1.78B
Beta
0.59
P/E (TTM)
-4.7
EPS (TTM)
-$7.19
52W Low $22.24High $46.00

Volume 0.60M

Average 1.11M

AGIO Short-term Investments

Marketable securities and deposits the company expects to convert to cash within a year.

Agios Pharmaceuticals, Inc.NASDAQ: AGIO

Short-term Investments · Q1 FY2026 · quarter ended Mar 2026

Short-term investments falls 23.4% from a year ago

Short-term investments stood at $623.44M at the end of Q1 FY2026, down 23.4% from a year earlier and down 18.5% from the prior quarter. Over 3 fiscal years it compounded at +5.9% a year.

Context

  • Short-term investments amounted to 52.6% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
  • Short-term investments increased in 2 of the last 3 fiscal years.

What to watch

Whether short-term investments keeps falling in the next quarterly balance sheet after a -23.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$623.44M-18.5% QoQ
Last fiscal yearDec 2025
$765.3M-6.4% YoY
Year agoMar 2025
$814.41M-23.4% since
Short-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.4%——
1 year-6.4%——
3-year CAGR+5.9%——
5-year CAGR——
10-year CAGR——

Short-term Investments history

USD · from the balance sheet

Latest · FY2025
765.3M USD
Year-over-year change
-6.4%
4-year CAGR
-1.6%

Short-term Investments vs competitors

How AGIO compares with its peers on the latest reported figures

  • AGIO's Mar 2026 short-term investments of $623.44M is the 2nd highest of the 7 companies compared; the peer median is $217.8M.
  • Its year-over-year change of -23.4% is the 6th highest of 7, against a peer median of +23.0%.
  • Short-term investments amounts to 52.6% of total assets for AGIO, versus a peer median of 29.7%.
AGIO Competitors Peer median
Short-term Investments for AGIO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PTCTPTC Therapeutics, Inc.Jun 2026$1.18B +21.3%+94.4%36.3%
AGIOAgios Pharmaceuticals, Inc.Mar 2026$623.44M -23.4%+5.9%52.6%
IRONDisc Medicine, Inc.Sep 2026$592.83M +24.7%—84.8%
RAREUltragenyx Pharmaceutical Inc.Mar 2026$238M -35.2%-25.0%18.4%
BCRXBioCryst Pharmaceuticals, Inc.Jun 2026$197.6M +14.9%+15.7%35.4%
PHARPharming Group N.V.Mar 2026$117.8M +149.7%—24.1%
MIRMMirum Pharmaceuticals, Inc.Jun 2026$107.56M +40.7%-11.2%10.3%
Peer median (excluding AGIO) $217.8M+23.0%+2.2%29.7%

Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents203.13M139.26M88.21M76.25M89.13M
Short-term Investments816.89M643.86M688.72M817.46M765.3M
Net Receivables4.38M2.21M2.81M4.11M10.58M
Inventory08.49M19.08M27.62M32.92M
Other Current Assets038.96M35.02M40.17M44.13M
Total Current Assets1.06B832.77M833.84M965.6M942.05M
Property, Plant & Equipment (Net)104.23M88.12M69.79M54.55M41.23M
Goodwill00000
Intangible Assets00000
Long-term Investments266.38M313.87M29.44M638.32M310.01M
Tax Assets00000
Other Non-current Assets2.9M3.96M4.06M4.72M3.93M
Total Non-current Assets373.51M405.95M103.28M697.6M355.17M
Total Assets1.44B1.24B937.12M1.66B1.3B
Account Payables16.7M18.62M9.78M16.64M18.36M
Short-term Debt000018.39M
Tax Payables000871K0
Deferred Revenue00000
Other Current Liabilities19.82M12.25M23.23M29.94M18.2M
Total Current Liabilities59.83M62.63M67.96M81.16M82.21M
Long-term Debt000021.82M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities03.28M1.16M880K(21.73M)
Total Non-current Liabilities85.94M75.28M58.14M41.09M21.91M
Total Liabilities145.76M137.9M126.1M122.24M104.11M
Common Stock71K71K72K73K75K
Retained Earnings(238.76M)(470.56M)(822.65M)(148.92M)(561.71M)
Accumulated OCI(1.2M)(12.54M)(441K)(1.52M)2.19M
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.29B1.1B811.02M1.54B1.19B
Total Debt97.09M85.66M72M56.99M62.02M
Net Debt(106.03M)(53.6M)(16.21M)(19.26M)(27.11M)

Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.